Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) — ()
Key Metrics
News
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
Published: by:
Sentiment: Positive ()
I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo …
Read More
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
Published: by:
Sentiment: Positive ()
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
Read More
New Year, New Strategy: Navigating Weight Loss ETFs
Published: by:
Sentiment: Positive ()
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. …
Read More
5 Sector ETFs Up 10% Despite February's Market Slump
Published: by:
Sentiment: Negative ()
The U.S. stocks disappointed investors in Feb amid slowdown concerns and tariffs. These ETFs still gained in double digits.
Read More
About Roundhill Investments - GLP-1 & Weight Loss ETF OZEM
Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.